Question 1

How do I know if a peptide has been studied in humans?

Accepted Answer

Start by separating human studies from preclinical, mechanistic, or anecdotal signals, then check the study population, endpoint, comparator, and source quality. A human study is evidence about the studied product and question; it is not automatic proof that every formulation, use, or claim transfers. Use the GLP-1 dossier for the evidence map and the Compound Desk for the underlying source trail.

Question 2

What's the difference between FDA-approved and compounded?

Accepted Answer

FDA approval applies to a specific product, indication, labeling, and manufacturing standard. A compounded product is prepared under a different regulatory pathway and should not be described as FDA-approved simply because it contains the same active ingredient. Keep the product, indication, source, and current regulatory status distinct, then return to a licensed clinician for an individual decision.

Question 3

Where do I find evidence for retatrutide?

Accepted Answer

Use the Retatrutide Evidence Dossier for the education-only interpretation of human-study signals, investigational boundaries, and open safety questions. Then open the retatrutide Compound Desk trail to see how the status and claims connect back to normalized source records. The dossier is for understanding evidence, not for treatment instructions or self-directed use.

Question 4

How should I read a Compound Desk source trail?

Accepted Answer

Treat the source trail as an audit path, not a recommendation. Begin with the status label and summary, inspect the dated regulatory or peer-reviewed records, and compare each source with the exact compound and question being discussed. The desk helps you see provenance and limits; it does not replace current regulatory review or clinical judgment.

Question 5

Does evidence for one GLP-1-family product transfer to another?

Accepted Answer

Not automatically. Shared class or pathway language can provide context, but evidence remains product-specific: molecule, formulation, dose, population, endpoint, indication, and safety record all matter. Compare the family overview with the individual semaglutide and tirzepatide dossiers, and keep any patient-specific question with a licensed clinician.

Question 6

What does the $500 Founders purchase include?

Accepted Answer

The $500 Founders purchase includes the first year of Standard patient portal and Q&A access. Standard renews at $1,200/year after that first year if the clinic does not choose Premium.

Question 7

When can a clinic add Premium, and what does it cost?

Accepted Answer

Premium may be added any time after the $500 Founders purchase for $299/month, with billing starting upon activation. The $500 purchase is separate from Premium and receives no credit or proration toward it. No separate $1,200 annual Standard renewal charge applies while Premium remains active. Clinic branding is included in Premium.

Question 8

Are monthly practitioner research updates, recipes, or a patient journal available?

Accepted Answer

No. Monthly practitioner research updates, recipes, and a patient journal are unavailable and are not included in the current offer.